The bladder cancer targeting drug erdafitinib of Johnson&Johnson was approved in the EU
因醉鞭名马幌
发表于 2024-8-24 14:04:25
242
0
0
On August 23rd, Janssen Cilag International NV, a subsidiary of Johnson&Johnson, announced that the European Commission (EC) has approved BALVERSA& reg; (erdafitinib) is a daily oral monotherapy used to treat adult patients with unresectable or metastatic urothelial carcinoma (mUC).
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Trump claims to have received a call from Cook seeking help regarding Apple being fined heavily by the European Union
- トランプ氏、クック氏からの「助けを求める」電話にアップルがEUから巨額の罰金を科されたと主張
- ノフノイド：スミグロルペプチド2.4 mgは肝線維化症状の顕著な改善を示し、2025年上半期に米国とEUに規制承認を提出する
- EU、中国企業への制裁を提案外交部：欧州側に二重基準にしないよう促す
- Ford, Bosch, Schaeffler significantly lay off employees, casting a shadow over the EU automotive industry
- フォード、ボッシュ、シェフラーが大幅リストラ、EU自動車産業に暗雲
- Apple denounces Meta for taking advantage, but this time the EU stands with Meta
- アップルはメッタを激しく非難したがEUは今度はメッタに味方した
- Trump threatens EU in post: Buy our oil and gas or tariffs will serve!
- トランプ氏はEUを脅迫する投稿をした：私たちの石油と天然ガスを購入しないと関税が待っている！